161 related articles for article (PubMed ID: 15646066)
1. Host factors and efficacy of antiretroviral treatment.
Turriziani O; Antonelli G
New Microbiol; 2004 Apr; 27(2 Suppl 1):63-9. PubMed ID: 15646066
[TBL] [Abstract][Full Text] [Related]
2. Cellular issues relating to the resistance of HIV to antiretroviral agents.
Turriziani O; Scagnolari C; Bellomi F; Solimeo I; Focher F; Antonelli G
Scand J Infect Dis Suppl; 2003; 106():45-8. PubMed ID: 15000583
[TBL] [Abstract][Full Text] [Related]
3. ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages.
Jorajuria S; Dereuddre-Bosquet N; Becher F; Martin S; Porcheray F; Garrigues A; Mabondzo A; Benech H; Grassi J; Orlowski S; Dormont D; Clayette P
Antivir Ther; 2004 Aug; 9(4):519-28. PubMed ID: 15456083
[TBL] [Abstract][Full Text] [Related]
4. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
[TBL] [Abstract][Full Text] [Related]
5. Non-steroidal anti-inflammatory drugs increase the antiretroviral activity of nucleoside reverse transcriptase inhibitors in HIV type-1-infected T-lymphocytes: role of multidrug resistance protein 4.
Clemente MI; Alvarez S; Serramía MJ; Turriziani O; Genebat M; Leal M; Fresno M; Muñoz-Fernández MA
Antivir Ther; 2009; 14(8):1101-11. PubMed ID: 20032540
[TBL] [Abstract][Full Text] [Related]
6. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
Joly V; Descamps D; Yeni P
AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
[TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of the effect of temporary removal of HIV drug pressure.
Witvrouw M; Pannecouque C; Desmyter J; De Clercq E; Andries K
Antiviral Res; 2000 Jun; 46(3):215-21. PubMed ID: 10867159
[TBL] [Abstract][Full Text] [Related]
8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
[TBL] [Abstract][Full Text] [Related]
10. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
Benito JM; López M; Martín JC; Lozano S; Martínez P; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1379-88. PubMed ID: 12487809
[TBL] [Abstract][Full Text] [Related]
11. Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules.
Hoggard PG; Back DJ
Curr Opin Infect Dis; 2002 Feb; 15(1):3-8. PubMed ID: 11964899
[TBL] [Abstract][Full Text] [Related]
12. The role of breast cancer resistance protein (BCRP/ABCG2) in cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.
Wang X; Baba M
Antivir Chem Chemother; 2005; 16(4):213-6. PubMed ID: 16130519
[TBL] [Abstract][Full Text] [Related]
13. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
[TBL] [Abstract][Full Text] [Related]
14. 1, 2, 3-current ways to fight HIV.
Vazquez E
Posit Aware; 1998; 9(6):31-3. PubMed ID: 11366478
[TBL] [Abstract][Full Text] [Related]
15. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
[No Abstract] [Full Text] [Related]
16. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?
Garbelli A; Riva V; Crespan E; Maga G
Biochem J; 2017 Apr; 474(10):1559-1577. PubMed ID: 28446620
[TBL] [Abstract][Full Text] [Related]
17. Cellular factors for resistance against antiretroviral agents.
Fridland A; Connelly MC; Robbins BL
Antivir Ther; 2000 Sep; 5(3):181-5. PubMed ID: 11075937
[TBL] [Abstract][Full Text] [Related]
18. The development of anti-HIV-1 drugs.
Lu XF; Chen ZW
Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
[TBL] [Abstract][Full Text] [Related]
19. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
[TBL] [Abstract][Full Text] [Related]
20. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Miller V; Larder BA
Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
